Diabetic Neuropathy report offers the rapeutic assessment
with comparative analysis at several stages, drug target, route of
administration (RoA), mechanism of action (MoA) and molecule type. This guide
covers the descriptive pharmacological action of the therapeutics along with
its complete research and development history along with latest news &
press releases.
Diabetic Neuropathy Industry |
As the name suggests, Diabetic
Neuropathy Industry is a nerve disorder caused by diabetes, also
referred as Metabolic Disorder. The longer a person has been diabetic, the
danger of diabetic neuropathy increases. This nerve damage can manifest itself
anywhere in the body, such as heart, sex organs and the digestive system. The
influencing factors are obesity, hypertension, high lipid and sugar levels,
smoking etc. It further leads to lack of sensation, tingling in hands, arms and
feet. The report estimates that more than 50 percent of people who have
diabetes are affected by some type of neuropathy and maximum rates of
neuropathy are amongst the public who have had diabetes for close to 25 years.
It is not limited only to diabetic patients but it could also affect people who
are not able to control their blood pressure or are overweight. People who are
above 40 years of age are also affected by neuropathy.
The study observes that, Diabetic
Neuropathy Report can be managed through medication and dietary
modification. Pain relieving treatment includes anti-seizure medications such
as gabapentin, pregabalin & carbamazepine, anti-depressants medications and
capsaicin cream. In addition to this, nitrate sprays or patches for the feet may
also relieve pain. The guide also covers the drug profiles used by the
companies for the therapy along with the product description, mechanism of
action and R&D progress. Additionally, various dynamic tracking processes
ensure that the most recent developments are bagged on a real time basis.
Companies involved in Therapeutics Development of Diabetic
Neuropathy are listed below:
- Achelios Therapeutics, Inc.
- KPI Therapeutics, Inc.
- Araim Pharmaceuticals, Inc.
- Celgene Corporation
- Commence Bio, Inc.
- NovaLead Pharma Pvt. Ltd.
- Glucox Biotech AB
- Lpath, Inc.
- Medifron DBT Co., Ltd.
- Neuralstem, Inc.
- Novartis AG
- Relief Therapeutics S.A.
- Omeros Corporation
- PhiloGene, Inc.
- Reata Pharmaceuticals, Inc.
- Sucampo Pharmaceuticals, Inc.
- ViroMed Co Ltd
Further, the report features investigational drugs from
across the globe covering over 20 therapy areas and nearly 3,000 indications.
Additionally, report also summarizes all the dormant and discontinued pipeline
projects.